For the first time we report the design and syntheses of phosphonite coordinated ruthenium(II) sensitizers bearing ĈN̂N ligand and/or terpyridine derivatives carboxylate anchor (GS11, GS12. and GS13) and its application for hydrogen production over Pt-TiO2 system. These heteroleptic complexes exhibit broad metal-to-ligand charge transfer transition band over the whole visible regime extending up to 900 nm. DFT calculations of these complexes show that the HOMO is distributed over the Ru and Cl atom whereas; LUMO is localized on the polypyridile ligand, which are anchored on TiO2 surface. Among the sensitizers tested for photocatalytic hydrogen evolution, GS12 exhibited a maximum turnover number (TON) 8605 (for 8 h), which is very high compared to the reference sensitizer (N719) with TON 163 under similar evaluation condition. The dependence of the hydrogen evolution rate at different pH using GS11, GS12, GS13, and DX-1-sensitized Pt-TiO2 has been studied and the maximum H2 production yield was obtained at pH 7 for all sensitizers.

2009-04-09·Journal of Medicinal Chemistry1区 · 医学

Effect of Ring Size on Conformation and Biological Activity of Cyclic Cationic Antimicrobial Peptides

1区 · 医学

Article

作者: Wheaton, Laura C. ; Jelokhani-Niaraki, Masoud ; Hodges, Robert S. ; Kondejewski, Leslie H.

In a series of cyclic peptides based on GS10, an analogue of gramicidin S (GS), the ring size was varied from 10 to 16 amino acids. Alternative addition of basic and hydrophobic amino acids to the original GS10 construct generated a variety of even-numbered rings, i.e., GS10 [cyclo-(VKLdYPVKLdYP)], GS12 [cyclo-(VKLKdYPKVKLdYP)], GS14 [cyclo-(VKLKVdYPLKVKLdYP), and GS16 [cyclo-(VKLKVKdYPKLKVKLdYP)] (d stands for d-enantiomers). The odd-numbered analogues (11-, 13-, and 15-mers) were derived from these four peptides by either addition or deletion of single basic (Lys) or hydrophobic (Leu or Val) amino acids. The resulting peptides, divided into three groups on the basis of peptide ring size (10- to 12-meric, 13- and 14-meric, and 15- and 16-meric), illustrated a diverse spectrum of biological activity correlated to their ring size, degree of beta-structure disruption, charge, hydrophobicity, amphipathicity, and affinity for lipid membranes. Two of these peptides with potent antimicrobial activities and high therapeutic indexes (4.5- to 10-fold compared with GS) are promising candidates for development of broad-spectrum antibiotics.

2002-07-01·The Journal of Peptide Research

Conformation and interaction of the cyclic cationic antimicrobial peptides in lipid bilayers

Article

作者: R.N. McElhaney ; E.J. Prenner ; C.M. Kay ; R.S. Hodges ; M. Jelokhani-Niaraki

Abstract: To investigate the role of peptide–membrane interactions in the biological activity of cyclic cationic peptides, the conformations and interactions of four membrane‐active antimicrobial peptides [based on Gramicidin S (GS)] were examined in neutral and negatively charged micelles and phospholipid vesicles, using CD and fluorescence spectroscopy and ultracentrifugation techniques. Moreover, the effects of these peptides on the release of entrapped fluorescent dye from unilamellar vesicles of phosphatidylcholine (PC) and phosphatidylethanolamine/phosphatidylglycerol (PE/PG) were studied. The cyclic peptides include GS10 [Cyclo(VKLdYP)2], GS12 [Cyclo(VKLKdYPKVKLdYP)], GS14 [Cyclo(VKLKVdYPLKVKLdYP)] and [d‐Lys]4GS14 [Cyclo(VKLdKVdYPLKVKLdYP)] (underlined residues are d‐amino acids), were different in their ring size, structure and amphipathicity, and covered a broad spectrum of hemolytic and antimicrobial activities. Interaction of the peptides with the zwitterionic PC and negatively charged PE/PG vesicles were distinct from each other. The hydrophobic interaction seems to be the dominant factor in the hemolytic activity of the peptides, as well as their interaction with the PC vesicles. A combination of electrostatic and hydrophobic interactions of the peptides induces aggregation and fusion in PE/PG vesicles with different propensities in the order: [d‐Lys]4GS14 > GS14 > GS12 > GS10. GS10 and GS14 are apparently located in the deeper levels of the membrane interfaces and closer to the hydrophobic core of the bilayers, whereas GS12 and [d‐Lys]4GS14 reside closer to the outer boundary of the interface. Because of differing modes of interaction of the cyclic cationic peptides with lipid bilayers, the mechanism of their biological activity (and its relation to peptide–lipid interaction) proved to be versatile and complex, and dependent on the biophysical properties of both the peptides and membranes.

项与 GS12 相关的新闻（医药）

2022-08-17

·泽璟制药

泽璟制药第二个双功能抗体ZGGS18临床试验申请获得国家药监局批准

近日，泽璟制药收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司自主研发的注射用ZGGS18（VEGF/TGF-β）用于治疗晚期实体瘤的临床试验获得批准。根据公开数据查询，目前暂无相同作用机制的药品在国内外获批上市或进入临床研究。这是继ZG005（PD-1/TIGIT）后，泽璟制药第二个获国家药监局批准开展临床试验的双特异性抗体类药物。此前，ZGGS18、ZG005用于治疗实体瘤的临床试验申请均已获得美国FDA批准，实现中美双报，标志着公司的新型抗体研发平台逐步步入收获期。 ZGGS18、ZG005有望成为治疗实体瘤的肿瘤免疫创新型生物制品，丰富泽璟制药分子靶向和肿瘤免疫双管齐下的肿瘤药产品管线。在生物医药领域，肿瘤免疫和分子靶向联合治疗已经显示出突出的治疗效果，将是未来肿瘤治疗的重要趋势。ZGGS18、ZG005和公司小分子靶向新药等具有联合协同增效作用，将能增强公司在肿瘤治疗领域的竞争优势。关于ZGGS18 ZGGS18是公司及子公司Gensun Biopharma Inc.通过双/多特异性抗体研发平台开发的一个双功能抗体融合蛋白药物，也是公司递交临床试验申请的第二个双特异性抗体类药物。ZGGS18的注册分类为治疗用生物制品1类，有望成为治疗实体瘤的创新型生物制品。 ZGGS18是一种重组人源化抗VEGF/TGF-β的双功能抗体融合蛋白，可以特异性地结合血管内皮生长因子（VEGF）和“捕获”转化生长因子-β（TGFβ），起到抑制肿瘤新生血管形成和降低肿瘤转移发生等协同抑制肿瘤生长的多重作用。另外，ZGGS18也可以改善和调节肿瘤微环境，从而可以和抗PD-1/L1抗体、公司正在开展临床研究的抗PD-1/TIGIT双特异性抗体ZG005等肿瘤免疫治疗药物联合增强肿瘤杀伤作用。临床前研究结果显示，ZGGS18在人非小细胞肺癌、结直肠癌等模型上具有显著的肿瘤抑制作用，且在和抗PD-1抗体联合治疗后，可以导致显著比例的小鼠肿瘤完全消退，说明ZGGS18具有强效的肿瘤杀伤作用和增强肿瘤免疫治疗药物疗效的潜力。ZGGS18在非人灵长类动物中显示出长半衰期等优良的药代动力学特征及良好的安全性特征。关于子公司GENSUN 子公司GENSUN（Gensun Biopharma Inc.）致力于发现和开发新型抗体。GENSUN拥有三个候选药物研发平台TriGen、CheckGen和TGen。TriGen平台为三特异抗体研发平台，可以突破抗体两个Fab段的限制，赋予分子结合三个不同靶点的能力。CheckGen平台可以产生以免疫检查点为靶点的双特异抗体候选新药。TGen平台为新型双特异抗体分子开发平台，所产生的候选药物分子可以用作单一药物治疗，可以彼此组合联合用药，也可以与抗PD1/PD-L1治疗药物组合。 GENSUN的产品线包括GS01、GS02、GS10、GS11、GS12、GS14、GS15、GS17、GS18、GS19等10余个在研项目。GENSUN累计申请专利40项，共获授权8项。GENSUN授予齐鲁制药GS02（针对TIGIT靶点）大中华地区的专利独家授权，授予开拓药业GS19（PD-L1/TGF-beta）在大中华区的专利独家授权。内容来源于网络，如有侵权，请联系删除。

抗体临床获批

100 项与 GS12 相关的药物交易

登录后查看更多信息